Skip to main content

Advertisement

Table 1 CDC42-mediated relative mAb-titer increase over native clone titers. The clones represent five different products.

From: Biosynthetic pathway deflection – a new cell line engineering approach

Titers of Naïve mAb producing clones
[g/l]
Titers of cdc42-engineered mAb producing clones
[g/l]
Relative Fold Increase per modified clone
0,8 1,65 2,06
0,9 2,2 2,4
2,3 3,0 1,3
2,6 4,5 1,73
0,8 1,65 2,06